PolTREG
Pre-clinicalPTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis
Founded
2011
Focus
Cell & Gene Therapy
About
PTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis
Funding History
2Total raised: $16M
Series A$10MMedicoverJun 15, 2021
Grant$6MEuropean UnionJun 15, 2020
Company Info
TypePrivate
Founded2011
LocationGdańsk, Poland
StagePre-clinical
Contact
SIMILAR COMPANIES
AILIS Breast Cancer
Pre-clinical · Warsaw
Biocam
Pre-clinical · Warsaw
Bioton
Pre-clinical · Warsaw
Ensera
Pre-clinical · Warsaw
Biovico
Pre-clinical · Warsaw
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile